MedTrace Logo

3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

NCT05265052 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2026-03-11

No results posted yet for this study

Summary

This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.

Conditions

  • Cancer Pain

Interventions

DRUG

3D1002 (50 mg)(Phase IIa)

1 tablet of 3D1002 per oral dose

DRUG

3D1002 (100 mg)(Phase IIa)

2 tablets of 3D1002 per oral dose

DRUG

3D1002 (150 mg)(Phase IIa)

3 tablets of 3D1002 per oral dose

DRUG

3D1002 monotherapy (Phase IIb)

3D1002 is administered at recommended dose with mimic OxyContin tablets.

DRUG

OxyContin monotherapy (Phase IIb)

OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.

DRUG

3D1002 + OxyContin (Phase IIb)

3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.

Sponsors & Collaborators

  • 3D Medicines

    lead INDUSTRY

Principal Investigators

  • Suxia Luo · Henan Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-31
Primary Completion
2026-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05265052 on ClinicalTrials.gov